Launch · 30th April 2026
ALP Bio AG raises $2.2M pre-seed led by 42CAP to de-risk antibody development with immunogenicity intelligence.
By – The ALP Bio Team
Funding will accelerate ALP Bio’s immune organoid and AI platform for earlier prediction and mitigation of immunogenicity and anti-drug antibody risk in biologics development.
- ALP Bio combines human immune organoid biology with generative AI to identify, understand, and reduce immunogenicity risk earlier in antibody development.
- Immunogenicity and anti-drug antibody (ADA) responses remain among the most costly hidden risks in biologics, often surfacing only in late-stage clinical trials.
- Pre-seed round led by Munich-based 42CAP, with participation from Venture Kick and angel investors.
SCHLIEREN, Switzerland & SAN DIEGO, USA — 30th April 2026 — ALP Bio AG today announced it has raised USD 2.2 million (EUR 1.9M / CHF 1.75M) in pre-seed financing led by Munich-based VC 42CAP, with participation from Venture Kick and a group of strategic angel investors. The funding will accelerate ALP Bio’s platform, which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
The hidden risk in biologics development
Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks in biologics development. These immune responses can reduce therapeutic efficacy, create safety concerns, and force teams to abandon or rework programs late in development, after they have already consumed significant time and capital. Today, most immunogenicity signals only emerge in clinical trials, when the cost of course correction is highest.
A hybrid platform for earlier, actionable signal
ALP Bio is building a hybrid platform designed to bring more clinically relevant signal into earlier antibody decision-making. The company combines experimentally measured human immune organoid readouts with machine learning models that support risk assessment and antibody redesign. By integrating wet-lab immune biology with scalable computational design, ALP Bio aims to move developers from late-stage failure toward earlier, more actionable immunogenicity intelligence.
The platform builds on human tonsil organoid technology, which models relevant immune activity in vitro, and AI models designed to learn from increasingly rich biological datasets. ALP Bio is developing the platform to support lead candidate screening, ADA risk stratification, and sequence optimization while preserving therapeutic function.
“Immunogenicity is one of the largest hidden costs in biologics, and the industry has accepted late-stage surprises as the norm for too long. We believe this risk should be measured and reduced years earlier than it is today. This financing lets us scale the experimental and computational foundation of our platform and partner with teams who want to make antibody development more predictable from the start.”
Dr. Christian Vahlensieck, CEO of ALP Bio AG
“Our scientific conviction is that immunogenicity cannot be solved by computation alone. By combining human immune organoid readouts with AI, we can generate the type of biological feedback needed to make antibody design more informed, iterative, and ultimately more useful for discovery and optimization teams.”
Dr. Lucas Schaus, CSO of ALP Bio AG
“ALP Bio is doing for biologics what high-throughput screening did for small molecules: collapsing a years-long bottleneck into a tractable design loop. Immunogenicity has held back the field for decades, and the team’s combination of immune organoid biology and sequence-level AI is the most credible attempt we have seen to address it at the source. This is exactly the kind of frontier BioIT bet, deep science with a clear commercial wedge, where we back founders with real conviction. Christian, Lucas, and the team bring the scientific depth and commercial discipline a problem of this size demands.”
Thomas Wilke, Partner at 42CAP
Use of funds
The pre-seed round will be deployed to:
- Expand ALP Bio’s experimental immune organoid capabilities and increase automation and throughput.
- Launch early partner projects focused on immunogenicity risk in antibody lead candidates.
- Build out scientific and commercial capacity in Switzerland and the US.
ALP Bio is now engaging pharmaceutical and biotechnology partners interested in early-access collaborations on immunogenicity. The company is particularly focused on antibody programs where earlier de-risking could improve candidate selection, reduce downstream uncertainty, and support better development decisions.
About ALP Bio AG
ALP Bio AG is developing an immune organoid and AI platform for immunogenicity intelligence in biologics development. The company combines human immune organoid readouts with generative AI to help drug developers predict and reduce anti-drug antibody risk earlier in antibody discovery and development. ALP Bio is headquartered in Schlieren, Switzerland, with operations in San Diego, USA and partnerships across the international biotech ecosystem.
About 42CAP
42CAP is a Munich-based venture capital firm investing in technical founders building category-defining software and BioIT companies in Europe. The firm partners with founders from pre-seed onward and is known for taking conviction-led positions in deep technology bets.